Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.9 USD | +4.69% | +0.69% | +2.11% |
May. 23 | DiaMedica Therapeutics Inc. Elects Rick Pauls as Director | CI |
May. 09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 75.63 | 241.8 | 124.6 | 56.61 | 142.8 | 150.2 | - | - |
Enterprise Value (EV) 1 | 75.63 | 207 | 124.6 | 56.61 | 142.8 | 150.2 | 150.2 | 150.2 |
P/E ratio | -5.45 x | -13 x | -5.74 x | -3.04 x | -4.73 x | -4.18 x | -3.37 x | -4.14 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | -4.49 x | -17.6 x | - | - | -4.96 x | -3.85 x | -2.78 x | -2.75 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 12,007 | 18,739 | 26,439 | 26,443 | 37,954 | 37,964 | - | - |
Reference price 2 | 4.850 | 10.14 | 3.730 | 1.580 | 2.840 | 2.900 | 2.900 | 2.900 |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA 1 | -16.83 | -13.7 | - | - | -28.81 | -39 | -54.05 | -54.6 |
EBIT 1 | -16.86 | -16.06 | -17.41 | -19.07 | -28.85 | -38.11 | -48.99 | -54.74 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -15.44 | -15.51 | -17.31 | -18.59 | -26.24 | -36.17 | -47.35 | -54.74 |
Net income 1 | -15.49 | -15.55 | -17.34 | -18.63 | -26.3 | -36.08 | -47.35 | -54.74 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -0.8900 | -0.7800 | -0.6500 | -0.5200 | -0.6000 | -0.6933 | -0.8600 | -0.7000 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | -7.429 | -6.373 | -7.098 | -7.924 | -7.867 | -9.305 | -10.67 | -11.36 | -11.5 | -12.86 |
EBIT 1 | -4.142 | -4.535 | -4.294 | -4.209 | -5.412 | -7.452 | -6.383 | -7.109 | -7.934 | -7.878 | -9.032 | -10.26 | -11.02 | -11.5 | -12.86 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.133 | -4.49 | -4.277 | -4.107 | -5.1 | -7.106 | -6.018 | -6.154 | -6.972 | -7.059 | -8.598 | -9.762 | -10.23 | -11.5 | -12.86 |
Net income 1 | -4.142 | -4.499 | -4.286 | -4.116 | -5.109 | -7.116 | -6.027 | -6.164 | -7.002 | -7.069 | -8.566 | -9.762 | -10.23 | -11.5 | -12.86 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1100 | -0.1300 | -0.1300 | -0.1200 | -0.1400 | -0.2000 | -0.1600 | -0.1200 | -0.1400 | -0.1400 | -0.1633 | -0.1867 | -0.1967 | -0.2200 | -0.2500 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/14/22 | 5/4/22 | 8/10/22 | 11/9/22 | 3/28/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/19/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | 34.8 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/23/20 | 3/10/21 | 3/14/22 | 3/28/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.11% | 110M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- DMAC Stock
- Financials DiaMedica Therapeutics Inc.